Vigil Neuroscience, Inc. (VIGL) DCF Valuation

Vigil Neuroscience, Inc. (VIGL) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Vigil Neuroscience, Inc. (VIGL) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Whether you’re an investor or analyst, this (VIGL) DCF Calculator is your go-to resource for accurate valuation. Loaded with real data from Vigil Neuroscience, Inc., you can adjust forecasts and observe the effects in real time.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0
EBITDA -28.5 -42.9 -67.3 -88.5 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100
Depreciation 12.6 .3 1.0 .4 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100
EBIT -41.1 -43.3 -68.3 -88.9 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100
Total Cash 24.2 91.4 186.6 117.9 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 1.5
Account Receivables, % 100 100 100 100
Inventories .0 .0 10.6 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100
Accounts Payable 1.1 4.0 1.9 1.9 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100
Capital Expenditure -.5 -.2 -.9 -.7 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0
EBITAT -41.1 -43.3 -67.7 -88.9 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -27.9 -40.2 -80.2 -80.1 -.5 .0 .0 .0 .0
WACC, % 11.95 11.95 11.95 11.95 11.95 11.95 11.95 11.95 11.95
PV UFCF
SUM PV UFCF .0 .0 .0 .0 .0 .0 .0 .0 -.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 0
Net Debt -38
Equity Value 38
Diluted Shares Outstanding, MM 39
Equity Value Per Share 0.97

What You Will Get

  • Editable Forecast Inputs: Easily adjust key assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Vigil Neuroscience, Inc.'s (VIGL) financial data pre-filled to kickstart your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
  • Customizable and Professional: A refined Excel model that aligns with your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.

Key Features

  • Comprehensive Financial Data: Gain access to precise historical data and future forecasts for Vigil Neuroscience, Inc. (VIGL).
  • Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
  • Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
  • Interactive Dashboard: User-friendly charts and summaries to effectively visualize your valuation outcomes.
  • Designed for All Skill Levels: An intuitive layout tailored for investors, CFOs, and consultants alike.

How It Works

  • 1. Access the Template: Download and open the Excel file containing Vigil Neuroscience, Inc.'s preloaded data.
  • 2. Modify Assumptions: Adjust key parameters such as growth projections, WACC, and capital expenditures.
  • 3. View Results Immediately: The DCF model automatically computes the intrinsic value and NPV.
  • 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation results.
  • 5. Present with Assurance: Deliver professional valuation insights to back your strategic decisions.

Why Choose Vigil Neuroscience, Inc. (VIGL)?

  • Innovative Solutions: Cutting-edge research and therapies aimed at neurological disorders.
  • Expert Team: A dedicated group of professionals with extensive experience in neuroscience.
  • Strong Pipeline: Promising drug candidates that address unmet medical needs.
  • Commitment to Patients: Focused on improving the quality of life for individuals with neurological conditions.
  • Proven Track Record: Backed by successful collaborations and partnerships in the biotech industry.

Who Should Use Vigil Neuroscience, Inc. (VIGL)?

  • Healthcare Investors: Make informed decisions using advanced analytics tailored for the biotech sector.
  • Biotech Analysts: Streamline your research with comprehensive data and insights on VIGL's pipeline.
  • Consultants: Easily modify reports and presentations to highlight VIGL's strategic initiatives.
  • Science Enthusiasts: Expand your knowledge of neuroscience and biotechnology through real-time updates and case studies.
  • Educators and Students: Utilize VIGL as a case study in courses focused on biotechnology and investment strategies.

What the Template Contains

  • Preloaded VIGL Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.